Identification

Name
Lansoprazole
Accession Number
DB00448  (APRD00077)
Type
Small Molecule
Groups
Approved, Investigational
Description

Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid. It is manufactured by TAP Pharmaceutical Products. Lansoprazole has been marketed for many years and is one of several PPI's available.

Structure
Thumb
Synonyms
  • AG 1749
  • Bamalite
  • Lansoprazol
  • Lansoprazole
  • Lansoprazolum
  • Lanzol
  • Lanzopral
  • Lanzul
  • Limpidex
  • Monolitum
  • Ogastro
  • Opiren
External IDs
A 65006 / AG 1749
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LansoprazoleCapsule, delayed release15 mgOralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
LansoprazoleCapsule, delayed release30 mgOralPharmascience Inc2015-02-11Not applicableCanada
LansoprazoleCapsule, delayed release pellets15 mg/1OralApace Packaging, Llc2016-07-14Not applicableUs
LansoprazoleCapsule, delayed release30 mgOralSanis Health Inc2010-11-22Not applicableCanada
LansoprazoleCapsule, delayed release30 mgOralDominion PharmacalNot applicableNot applicableCanada
LansoprazoleCapsule, delayed release30 mg/1OralRebel Distributors2009-11-11Not applicableUs
LansoprazoleCapsule, delayed release30 mgOralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
LansoprazoleCapsule, delayed release15 mgOralSanis Health Inc2010-11-23Not applicableCanada
LansoprazoleCapsule, delayed release15 mgOralPharmascience Inc2015-01-13Not applicableCanada
LansoprazoleCapsule, delayed release pellets30 mg/1OralApace Packaging, Llc2016-07-14Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-lansoprazoleCapsule, delayed release30 mgOralApotex Corporation2009-06-03Not applicableCanada
Apo-lansoprazoleCapsule, delayed release15 mgOralApotex Corporation2009-06-03Not applicableCanada
Dom-lansoprazoleCapsule, delayed release30 mgOralDominion Pharmacal2014-07-08Not applicableCanada
Dom-lansoprazoleCapsule, delayed release15 mgOralDominion PharmacalNot applicableNot applicableCanada
LansoprazoleCapsule, delayed release30 mg/1OralRebel Distributors2009-11-11Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralBreckenridge Pharmaceutical, Inc.2012-12-18Not applicableUs
LansoprazoleCapsule, delayed release30 mg/1OralRemedy Repack2013-07-102017-03-03Us
LansoprazoleCapsule, delayed release15 mg/1OralAmerincan Health Packaging2012-01-012016-12-31Us
LansoprazoleTablet, orally disintegrating, delayed release30 mg/1OralPhysicians Total Care, Inc.2010-11-30Not applicableUs
LansoprazoleCapsule, delayed release15 mg/1OralBluePoint Laboratories2013-12-01Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Basic Care LansoprazoleCapsule, delayed release15 mg/1OralL. Perrigo Company2017-09-03Not applicableUs
Berkley and Jensen LansoprazoleCapsule, delayed release15 mg/1OralBJWC2012-05-22Not applicableUs
CareOne Acid ReducerCapsule, delayed release15 mg/1OralAmerican Sales Company2016-10-14Not applicableUs
CareOne LansoprazoleCapsule, delayed release15 mg/1OralAmerican Sales Company2012-05-242018-07-10Us
Dg Health LansoprazoleCapsule, delayed release15 mg/1OralDolgencorp2012-05-21Not applicableUs
Equaline LansoprazoleCapsule, delayed release15 mg/1OralSupervalu2012-05-21Not applicableUs
Equate Lansoprazole Delayed ReleaseCapsule, delayed release15 mg/1OralWalmart Stores2014-05-05Not applicableUs
Exchange Select LansoprazoleCapsule, delayed release15 mg/1OralArmy + Air Force Exchange Service2012-06-11Not applicableUs
Good Neighbor Pharmacy LansoprazoleCapsule, delayed release15 mg/1OralAmerisource Bergen2012-05-31Not applicableUs
Good Sense lansoprazoleCapsule, delayed release15 mg/1OralL. Perrigo Company2012-05-24Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-lansoprazole-amoxicillin-clarithromycinLansoprazole (30 mg) + Amoxicillin (500 mg) + Clarithromycin (500 mg)Capsule; Capsule, delayed release; Kit; TabletOralApotex CorporationNot applicableNot applicableCanada
Hp-pacLansoprazole (30 mg) + Amoxicillin (500 mg) + Clarithromycin (500 mg)Capsule; Capsule, delayed release; Kit; TabletOralTakeda1998-08-18Not applicableCanada
Lansoprazole, Amoxicillin and ClarithromycinLansoprazole (30 mg/1) + Amoxycillin trihydrate (500 mg/1) + Clarithromycin (500 mg/1)KitSandoz2014-03-04Not applicableUs
Lansoprazole, Amoxicillin and ClarithromycinLansoprazole (30 mg/1) + Amoxycillin trihydrate (500 mg/1) + Clarithromycin (500 mg/1)KitPrasco, Laboratories2015-03-03Not applicableUs
Lansoprazole, Amoxicillin, and ClarithromycinLansoprazole (30 mg/1) + Amoxycillin trihydrate (500 mg/1) + Clarithromycin (500 mg/1)KitTeva2013-09-092015-04-30Us00093 8055 14 nlmimage10 c2386123
Lansoprazole, Amoxicillin, ClarithromycinLansoprazole (30 mg/1) + Amoxycillin trihydrate (500 mg/1) + Clarithromycin (500 mg/1)KitRising Health, Llc.2016-10-14Not applicableUs57237 00120180913 8702 1lfom9c
Prevacid NaprapacLansoprazole (15 mg/1) + Naproxen (500 mg/1)KitTakeda2003-11-142008-06-30Us
PrevpacLansoprazole (30 mg/1) + Amoxycillin trihydrate (500 mg/1) + Clarithromycin (500 mg/1)KitPhysicians Total Care, Inc.2005-05-20Not applicableUs
PrevpacLansoprazole (30 mg/1) + Amoxycillin trihydrate (500 mg/1) + Clarithromycin (500 mg/1)KitTakeda1997-12-02Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
PrevacidLansoprazole (15 mg/1)SuspensionOralTAP Pharmaceuticals Inc.2007-08-032007-08-03Us
PrevacidLansoprazole (30 mg/5mL)InjectionIntravenousTAP Pharmaceuticals Inc.2006-09-192006-09-19Us
PrevacidLansoprazole (15 mg/1)SuspensionOralTakeda Pharmaceuticals America, Inc.2008-10-022008-10-02Us
PrevacidLansoprazole (15 mg/1)Tablet, orally disintegratingOralTAP Pharmaceuticals Inc.2007-08-032007-08-03Us
PrevacidLansoprazole (30 mg/1)Capsule, delayed releaseOralTAP Pharmaceuticals Inc.2007-08-032007-08-03Us
PrevacidLansoprazole (30 mg/1)SuspensionOralTAP Pharmaceuticals Inc.2007-08-032007-08-03Us
PrevacidLansoprazole (15 mg/1)Capsule, delayed releaseOralTAP Pharmaceuticals Inc.2007-08-032007-08-03Us
PrevacidLansoprazole (30 mg/1)SuspensionOralTakeda Pharmaceuticals America, Inc.2008-10-022008-10-02Us
PrevacidLansoprazole (30 mg/1)Tablet, orally disintegratingOralTAP Pharmaceuticals Inc.2007-08-032007-08-03Us
PREVACID NapraPAC 250Lansoprazole + NaproxenKitTap Pharmaceutical Products Inc.2006-11-302006-11-30Us
International/Other Brands
Agopton (Takeda) / Bamalite / Lansoloc (Cipla Medpro) / Lanzol (Cipla) / Lanzopral (Pharma Investi) / Lanzopran (Ranbaxy) / Limpidex (Sigma-Tau) / Monolitum (Salvat) / Ogast (Takeda) / Ogastro (Abbott) / Opiren (Almirall) / Prevacid / Prevacid 24HR (Novartis) / Prevacid IV (Novartis) / Prosogan (Takeda) / Takepron (Takeda) / Ulpax (Hormona) / Zoprol (Toprak) / Zoton (Pfizer)
Categories
UNII
0K5C5T2QPG
CAS number
103577-45-3
Weight
Average: 369.361
Monoisotopic: 369.075882012
Chemical Formula
C16H14F3N3O2S
InChI Key
MJIHNNLFOKEZEW-UHFFFAOYSA-N
InChI
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
IUPAC Name
2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole
SMILES
CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1

Pharmacology

Indication

For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.

Associated Conditions
Pharmacodynamics

Lansoprazole, an acid proton-pump inhibitor similar to omeprazole, is used as an untiulcer drug in the treatment and maintenance of healing of duodenal or gastric ulcers, erosive and reflux esophagitis, NSAID-induced ulcer, Zollinger-Ellison syndrome, and Barrett's esophagus. Lansoprozole is active against Helicobacter pylori. The plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion. Thus, the plasma elimination half-life is less than two hours, while the acid inhibitory effect lasts more than 24 hours.

Mechanism of action

Lansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but rather suppress gastric acid secretion by specific inhibition of the (H+,K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, Lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.

TargetActionsOrganism
APotassium-transporting ATPase alpha chain 1
inhibitor
Human
UMicrotubule-associated protein tauNot AvailableHuman
Absorption

The absorption of lansoprazole is rapid, with mean Cmax occurring approximately 1.7 hours after oral dosing, and relatively complete with absolute bioavailability over 80%.

Volume of distribution
Not Available
Protein binding

97%

Metabolism

Hepatic. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by (H+,K+)-ATPase within the parietal cell canaliculus, but are not present in the systemic circulation.

Route of elimination

Following single-dose oral administration of PREVACID, virtually no unchanged lansoprazole was excreted in the urine. In one study, after a single oral dose of 14C-lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces. This implies a significant biliary excretion of the lansoprazole metabolites.

Half life

1.5 (± 1.0) hours

Clearance
Not Available
Toxicity

Symptoms of overdose include abdominal pain, nausea and diarrhea.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Lansoprazole Action PathwayDrug action
Lansoprazole Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C19CYP2C19*2(A;A)A Allele, homozygoteEffect Directly StudiedPatients with this genotype have reduced metabolism of lansoprazole.Details
Cytochrome P450 2C19CYP2C19*3(A;A)A Allele, homozygoteEffect Directly StudiedPatients with this genotype have reduced metabolism of lansoprazole.Details
Multidrug resistance protein 1---(C;T)C Allele, heterozygoteEffect Directly StudiedPatients with this genotype have increased plasma concentration of lansoprazole.Details
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Lansoprazole.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Lansoprazole.
16-BromoepiandrosteroneThe metabolism of 16-Bromoepiandrosterone can be increased when combined with Lansoprazole.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be increased when combined with Lansoprazole.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be increased when combined with Lansoprazole.
5-androstenedioneThe metabolism of 5-androstenedione can be increased when combined with Lansoprazole.
6-Deoxyerythronolide BThe metabolism of Lansoprazole can be decreased when combined with 6-Deoxyerythronolide B.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be increased when combined with Lansoprazole.
AbemaciclibLansoprazole may decrease the excretion rate of Abemaciclib which could result in a higher serum level.
AbirateroneThe metabolism of Lansoprazole can be decreased when combined with Abiraterone.
Food Interactions
  • Avoid alcohol.
  • Food reduces bioavailabilty, but this has very little clinical impact.
  • Take 30-60 minutes before meals.

References

Synthesis Reference

Clarke Slemon, Bob Macel, "Preparation of omeprazole and lansoprazole." U.S. Patent US5374730, issued December, 1986.

US5374730
General References
Not Available
External Links
Human Metabolome Database
HMDB0005008
KEGG Drug
D00355
PubChem Compound
3883
PubChem Substance
46508975
ChemSpider
3746
BindingDB
47032
ChEBI
6375
ChEMBL
CHEMBL480
Therapeutic Targets Database
DAP000725
PharmGKB
PA450180
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Lansoprazole
ATC Codes
A02BD10 — Lansoprazole, amoxicillin and levofloxacinA02BC53 — Lansoprazole, combinationsA02BC03 — LansoprazoleA02BD03 — Lansoprazole, amoxicillin and metronidazoleA02BD07 — Lansoprazole, amoxicillin and clarithromycinA02BD09 — Lansoprazole, clarithromycin and tinidazoleA02BD02 — Lansoprazole, tetracycline and metronidazole
AHFS Codes
  • 56:28.36 — Proton-pump Inhibitors
FDA label
Download (114 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers5
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentCystic Fibrosis (CF)1
1CompletedTreatmentGastroesophageal Reflux Disease2
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHelicobacter Pylori1
1CompletedTreatmentLaryngopharyngeal Reflux1
1CompletedTreatmentNeoplasms, Advanced or Metastatic1
1RecruitingBasic ScienceHealthy Volunteers1
1TerminatedOtherHealthy Volunteers1
1TerminatedTreatmentHealthy Volunteers1
1Unknown StatusNot AvailableEndothelial Dysfunction1
1, 2CompletedTreatmentInfants, Premature / Reflux, Gastroesophageal1
1, 2CompletedTreatmentPain, Fracture, Sprain1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
2CompletedTreatmentAcute Gouty Arthritis / Moderate Renal Impairment1
2CompletedTreatmentEsophagitis1
2CompletedTreatmentEsophagitis / Reflux1
2CompletedTreatmentGastrointestinal Reflux / Preterm Infants1
2CompletedTreatmentHeartburn1
2RecruitingTreatmentAppendiceal Neoplasms / Pseudomyxoma Peritonei1
2RecruitingTreatmentCervical Cancers / Endometrial Cancers / Uterine Cancers1
2RecruitingTreatmentGastric Diffuse Large B-cell Lymphoma1
2TerminatedTreatmentDiabetes, Autoimmune / Diabetes, Diabetes Mellitus Type 11
2Unknown StatusTreatmentDiabetes, Diabetes Mellitus Type 11
2, 3TerminatedTreatmentAsthma Bronchial / Reflux, Gastroesophageal1
3CompletedPreventionDuodenal Ulcer / Gastric Ulcer (GU)4
3CompletedTreatmentAcute Gouty Arthritis1
3CompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)2
3CompletedTreatmentDuodenal Ulcer1
3CompletedTreatmentDuodenal Ulcer / Gastric Ulcer (GU)1
3CompletedTreatmentErosive Esophagitis(EE)3
3CompletedTreatmentErosive Esophagitis(EE) / Gastro-esophageal Reflux Disease (GERD)1
3CompletedTreatmentFrequent Heartburn1
3CompletedTreatmentGastric Ulcer (GU)1
3CompletedTreatmentHeartburn1
3CompletedTreatmentHuman Experimentation1
3CompletedTreatmentLarynx Disease1
3CompletedTreatmentOsteoarthritis (OA) / Peptic Ulcers1
3CompletedTreatmentPeptic Esophagitis / Reflux Esophagitis (RE)2
3RecruitingTreatmentAnti-Ulcer Agents / Digestive System Diseases / Enzyme Inhibitors / Gastric Ulcer (GU) / Gastrointestinal Agents / Gastrointestinal Diseases / Lansoprazole / Molecular Mechanisms of Pharmacological Action / Peptic Ulcers / Proton Pump Inhibitors1
3RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)2
3RecruitingTreatmentDuodenal Ulcer1
3RecruitingTreatmentErosive Esophagitis(EE)1
3TerminatedPreventionHaemorrhage / Malignant Neoplasm of Stomach1
3TerminatedTreatmentDuodenal Ulcer / Gastric Ulcer (GU)1
3TerminatedTreatmentErosive Esophagitis(EE)1
3Unknown StatusTreatmentDuodenal Ulcer / Gastric Ulcer (GU) / Gastritis / Helicobacter Infections1
3Unknown StatusTreatmentGastro-esophageal Reflux Disease (GERD)1
3Unknown StatusTreatmentPeptic Ulcers1
3WithdrawnTreatmentDiabetes, Diabetes Mellitus Type 11
4Active Not RecruitingPreventionPeptic Ulcers1
4Active Not RecruitingTreatmentErosive Esophagitis(EE)1
4Active Not RecruitingTreatmentReflux, Gastroesophageal1
4CompletedNot AvailableHealthy Volunteers1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedDiagnosticBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4CompletedTreatmentAcid Regurgitation / Heartburn / Nausea / Upper Abdominal Pain1
4CompletedTreatmentAsthma Bronchial1
4CompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4CompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Chronic Idiopathic Thrombocytopenic Purpura1
4CompletedTreatmentEpigastric Pain Syndrome / Functional Dyspepsia / Post Prandial Distress Syndrome1
4CompletedTreatmentErosive Esophagitis(EE)2
4CompletedTreatmentEsophagus, Barrett1
4CompletedTreatmentFunctional Dyspepsia / Peptic Ulcers1
4CompletedTreatmentFunctional Dyspepsia / Scarred Peptic Ulcer1
4CompletedTreatmentGastric Ulcer (GU)1
4CompletedTreatmentGastritis / Indigestion / Peptic Ulcers1
4CompletedTreatmentGastroesophageal Reflux Disease2
4CompletedTreatmentGastroesophageal Reflux Disease / Heartburn1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHelicobacter Infection1
4CompletedTreatmentHelicobacter Pylori Treatment Failure1
4CompletedTreatmentIndigestion / Peptic Ulcers1
4CompletedTreatmentLarynx Disease / Reflux, Gastroesophageal1
4CompletedTreatmentMultiple Endocrine Neoplasia / Zollinger-Ellison Syndrome1
4CompletedTreatmentOtitis Media With Effusion1
4CompletedTreatmentReflux Esophagitis (RE)1
4CompletedTreatmentReflux, Gastroesophageal2
4Enrolling by InvitationTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4Enrolling by InvitationTreatmentGastroesophageal Reflux Disease1
4Not Yet RecruitingScreeningCardiovascular Events / Gastro-esophageal Reflux Disease (GERD) / Safety Issues1
4Not Yet RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4TerminatedPreventionPatients Undergoing Elective Coronary Artery Bypass Graft1
4TerminatedTreatmentDysphonia / Pediatric Dysphonia1
4TerminatedTreatmentFunctional Dyspepsia1
4TerminatedTreatmentLaryngopharyngeal Reflux1
4Unknown StatusTreatmentAsthma Bronchial1
4Unknown StatusTreatmentCoronary Stenting1
4Unknown StatusTreatmentEradication Rate for Helicobacter1
4Unknown StatusTreatmentEradication Rates of the Two Regimens1
4Unknown StatusTreatmentGastro-esophageal Reflux Disease (GERD) / Nasal Obstruction / Rhinitis1
4Unknown StatusTreatmentPost-Tonsillectomy Activity / Post-Tonsillectomy Hydration / Post-Tonsillectomy Pain1
4Unknown StatusTreatmentUpper Gastrointestinal Hemorrhage1
4WithdrawnTreatmentLaryngopharyngeal Reflux1
4WithdrawnTreatmentReflux, Gastroesophageal1
Not AvailableCompletedNot AvailableAcute Stress Ulcer and Acute Gastric Mucosal Lesions1
Not AvailableCompletedNot AvailableCommunity Acquired Pneumonia (CAP) / Gastro-esophageal Reflux Disease (GERD)1
Not AvailableCompletedNot AvailableGastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions1
Not AvailableCompletedNot AvailableGastric or Duodenal Ulcers2
Not AvailableCompletedNot AvailableGastroesophageal Reflux Disease With Dyspepsia Symptoms1
Not AvailableCompletedNot AvailableHelicobacter Infections1
Not AvailableCompletedNot AvailablePeriodontitis, Chronic1
Not AvailableCompletedDiagnosticNeuroendocrine Carcinoma (Carcinoid)1
Not AvailableCompletedSupportive CareGlomerulonephritis / Glomerulonephritis membranous / Glomerulonephritis minimal lesion1
Not AvailableCompletedTreatmentAnti Platelet Effects1
Not AvailableCompletedTreatmentAsthma Bronchial1
Not AvailableCompletedTreatmentGastroesophageal Reflux Disease1
Not AvailableCompletedTreatmentOtitis Media With Effusion1
Not AvailableCompletedTreatmentPeptic ulcer haemorrhage1
Not AvailableCompletedTreatmentPolyps, Nasal / Reflux, Gastroesophageal1
Not AvailableNot Yet RecruitingNot AvailableGastro-esophageal Reflux Disease (GERD)1
Not AvailableRecruitingDiagnosticNon-erosive Reflux Disease (NERD) / Reflux, Gastroesophageal1
Not AvailableRecruitingTreatmentCompare the Response Rate of Atypical GERD After PPI Therapy1
Not AvailableTerminatedTreatmentObstructive Sleep Apnea (OSA) / Reflux, Gastroesophageal1
Not AvailableUnknown StatusPreventionPeptic Ulcers / Ulcer Complications1
Not AvailableWithdrawnTreatmentGastroesophageal Reflux Disease / Head and Neck Carcinoma / Oropharyngeal Cancers1

Pharmacoeconomics

Manufacturers
  • Matrix laboratories ltd
  • Teva pharmaceuticals usa
  • Takeda pharmaceuticals north america inc
  • Novartis consumer health inc
  • Sandoz inc
Packagers
  • Abbott Laboratories Ltd.
  • Advanced Pharmaceutical Services Inc.
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Cardinal Health
  • Caremark LLC
  • Direct Pharmaceuticals Inc.
  • Dispensing Solutions
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • Inventia Healthcare Pvt Ltd.
  • Lake Erie Medical and Surgical Supply
  • Mckesson Corp.
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Patheon Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Promex Medical Inc.
  • Redpharm Drug
  • Resource Optimization and Innovation LLC
  • Sandoz
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Takeda Pharmaceutical Co. Ltd.
  • TAP Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Va Cmop Dallas
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
Capsule; capsule, delayed release; kit; tabletOral
Capsule, delayed releaseOral15 mg/1
Capsule, delayed release pelletsOral15 mg/1
Capsule, delayed release pelletsOral30 mg/1
Tablet, orally disintegrating, delayed releaseOral30 mg/1
Capsule, delayed releaseOral15 mg
Capsule, delayed releaseOral30 mg/1
Capsule, delayed releaseOral30 mg
InjectionIntravenous30 mg/5mL
SuspensionOral15 mg/1
SuspensionOral30 mg/1
Tablet, orally disintegratingOral15 mg/1
Tablet, orally disintegratingOral30 mg/1
Tablet, orally disintegrating, delayed releaseOral15 mg/1
Tablet, delayed releaseOral15 mg
Tablet, delayed releaseOral30 mg
Injection, powder, for solutionIntravenous30 mg/5mL
Kit
Prices
Unit descriptionCostUnit
Prevacid SoluTab 100 15 mg Dispersible Tablet Box620.65USD box
Prevacid NapraPAC 84 15-500 mg Kit Box175.8USD box
Prevpac Miscellaneous32.02USD ea
Prevpac patient pack28.22USD each
Lansoprazole 100% powder27.54USD g
Prevacid iv 30 mg vial27.31USD vial
Prevacid dr 15 mg capsule6.25USD capsule
Prevacid SoluTab 30 mg Dispersible Tablet6.21USD dispersible tablet
Prevacid 15 mg capsule dr6.0USD capsule
Prevacid 30 mg capsule dr6.0USD capsule
Prevacid dr 30 mg capsule5.91USD capsule
Lansoprazole 15 mg Delayed Release Capsule5.9USD capsule
Lansoprazole 30 mg Delayed Release Capsule5.9USD capsule
Prevacid 15 mg solutab5.73USD tablet
Prevacid 30 mg solutab5.73USD tablet
Lansoprazole dr 15 mg capsule5.67USD capsule
Lansoprazole dr 30 mg capsule5.67USD capsule
Prevacid 30 mg Delayed Release Capsule4.45USD capsule
Prevacid 15 mg Delayed Release Capsule4.32USD capsule
Apo-Lansoprazole 15 mg Delayed Release Capsule1.17USD capsule
Apo-Lansoprazole 30 mg Delayed Release Capsule1.17USD capsule
Novo-Lansoprazole 15 mg Delayed Release Capsule1.17USD capsule
Novo-Lansoprazole 30 mg Delayed Release Capsule1.17USD capsule
Prevacid 24hr dr 15 mg capsule0.86USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4628098No1992-11-102009-11-10Us
CA2419067No2008-12-232021-08-17Canada
CA1327010No1994-02-152011-02-15Canada
US7399485Yes1998-11-262018-11-26Us
US6328994Yes1999-11-172019-11-17Us
US7875292Yes1999-11-172019-11-17Us
US7431942Yes1999-11-172019-11-17Us
US7396841Yes2002-02-172022-02-17Us
US9901546Yes1999-11-172019-11-17Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)178-182 °CNot Available
water solubility0.97 mg/LNot Available
logP1.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.25 mg/mLALOGPS
logP2.84ALOGPS
logP3.03ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)9.35ChemAxon
pKa (Strongest Basic)4.16ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area67.87 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity87.61 m3·mol-1ChemAxon
Polarizability34.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9972
Blood Brain Barrier+0.7007
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.547
P-glycoprotein inhibitor IInhibitor0.5357
P-glycoprotein inhibitor IINon-inhibitor0.8692
Renal organic cation transporterInhibitor0.5521
CYP450 2C9 substrateNon-substrate0.7826
CYP450 2D6 substrateNon-substrate0.8659
CYP450 3A4 substrateSubstrate0.6771
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8768
Ames testNon AMES toxic0.5858
CarcinogenicityNon-carcinogens0.7944
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8997 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8777
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-0udi-0090000000-502b719a981f262577ba
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-0uxr-0890000000-2734547f6dc584ba4877
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-053i-0930000000-94e6e179919ee803d567
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0900000000-1676d647709a023eb1d8
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0900000000-95a3126e9d69aa2812d6
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0900000000-0bb1e54ec8c7d6bb5746
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0900000000-52d969183040eb21720c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0900000000-bba914a2bd85fb3b0823
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-02u0-0900000000-10a04626464fa2bcd6f9
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-2900000000-14157d06ad23e343435e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-02t9-8900000000-025e7246e314127a8422
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03xr-9300000000-6a804721218ef90d3f61
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0290000000-a108432755e4f5916f6e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0390000000-b8a59093f6b667fae5e4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0fs9-0790000000-a2f5e86f6faaab508112
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00li-0940000000-cc60a0c246e3fc1399d6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0pvr-0910000000-3c73fbb04b031d6b077d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-1900000000-731f4b8d7ac3ecfe924e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-6900000000-9474d5b5b8646c57c023
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0aor-9400000000-1533765e29fdaabcfcfe
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-066s-9200000000-1a1318476ca6543b3482
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0339000000-30ca3e1162573d0632eb
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-2590000000-3562d6bdd29198e5bf3e
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzimidazoles
Sub Class
Sulfinylbenzimidazoles
Direct Parent
Sulfinylbenzimidazoles
Alternative Parents
Methylpyridines / Alkyl aryl ethers / Benzenoids / Imidazoles / Heteroaromatic compounds / Sulfoxides / Sulfinyl compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 4 more
Substituents
Sulfinylbenzimidazole / Alkyl aryl ether / Methylpyridine / Pyridine / Benzenoid / Azole / Imidazole / Heteroaromatic compound / Sulfoxide / Azacycle
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
sulfoxide, pyridines, benzimidazoles (CHEBI:6375)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium-exchanging atpase activity
Specific Function
Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
Gene Name
ATP4A
Uniprot ID
P20648
Uniprot Name
Potassium-transporting ATPase alpha chain 1
Molecular Weight
114117.74 Da
References
  1. Matheson AJ, Jarvis B: Lansoprazole: an update of its place in the management of acid-related disorders. Drugs. 2001;61(12):1801-33. [PubMed:11693467]
  2. Langtry HD, Wilde MI: Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs. 1997 Sep;54(3):473-500. [PubMed:9279507]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Structural constituent of cytoskeleton
Specific Function
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neu...
Gene Name
MAPT
Uniprot ID
P10636
Uniprot Name
Microtubule-associated protein tau
Molecular Weight
78927.025 Da
References
  1. Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB: Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. J Alzheimers Dis. 2010;19(2):573-89. doi: 10.3233/JAD-2010-1262. [PubMed:20110603]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Curi-Pedrosa R, Daujat M, Pichard L, Ourlin JC, Clair P, Gervot L, Lesca P, Domergue J, Joyeux H, Fourtanier G, et al.: Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther. 1994 Apr;269(1):384-92. [PubMed:8169844]
  2. Krusekopf S, Roots I, Hildebrandt AG, Kleeberg U: Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+ -ATPase inhibitors and other xenobiotics. Xenobiotica. 2003 Feb;33(2):107-18. [PubMed:12623754]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Krusekopf S, Roots I, Hildebrandt AG, Kleeberg U: Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+ -ATPase inhibitors and other xenobiotics. Xenobiotica. 2003 Feb;33(2):107-18. [PubMed:12623754]
  2. Curi-Pedrosa R, Daujat M, Pichard L, Ourlin JC, Clair P, Gervot L, Lesca P, Domergue J, Joyeux H, Fourtanier G, et al.: Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther. 1994 Apr;269(1):384-92. [PubMed:8169844]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Krusekopf S, Roots I, Hildebrandt AG, Kleeberg U: Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+ -ATPase inhibitors and other xenobiotics. Xenobiotica. 2003 Feb;33(2):107-18. [PubMed:12623754]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Curator comments
Very minor contribution to metabolism and not relevant at therapeutic concentrations.
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A: Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996 May;277(2):805-16. [PubMed:8627562]
  2. Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P: Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol. 1995 Feb;47(2):410-8. [PubMed:7870052]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
Curator comments
Very minor contribution to metabolism and not relevant at therapeutic concentrations. R-lansoprazole acts as a steroespecific inducer of the enzyme but the degree of activation varies depending on the substrate.
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Liu KH, Kim MJ, Jung WM, Kang W, Cha IJ, Shin JG: Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. Drug Metab Dispos. 2005 Feb;33(2):209-13. doi: 10.1124/dmd.104.001438. Epub 2004 Nov 10. [PubMed:15537834]
  3. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [PubMed:15258107]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C18
Uniprot ID
P33260
Uniprot Name
Cytochrome P450 2C18
Molecular Weight
55710.075 Da
References
  1. Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P: Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol. 1995 Feb;47(2):410-8. [PubMed:7870052]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA: Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997 Jul;25(7):853-62. [PubMed:9224780]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu KH, Chun JH, Hyun MH, Shin JG: Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos. 2003 Oct;31(10):1227-34. doi: 10.1124/dmd.31.10.1227. [PubMed:12975331]
  2. Curi-Pedrosa R, Daujat M, Pichard L, Ourlin JC, Clair P, Gervot L, Lesca P, Domergue J, Joyeux H, Fourtanier G, et al.: Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther. 1994 Apr;269(1):384-92. [PubMed:8169844]
  3. Masubuchi N, Li AP, Okazaki O: An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chem Biol Interact. 1998 Jul 3;114(1-2):1-13. [PubMed:9744552]
  4. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A: Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996 May;277(2):805-16. [PubMed:8627562]
  5. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA: Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997 Jul;25(7):853-62. [PubMed:9224780]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Curator comments
Higher affinity for S-lansoprazole but contributes to the metabolism of R-lansoprazole as well. This affinity is also proportional to the potency of each molecule as an inhibitor of the enzyme.
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A: Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996 May;277(2):805-16. [PubMed:8627562]
  3. Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu KH, Chun JH, Hyun MH, Shin JG: Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos. 2003 Oct;31(10):1227-34. doi: 10.1124/dmd.31.10.1227. [PubMed:12975331]
  4. Liu KH, Kim MJ, Shon JH, Moon YS, Seol SY, Kang W, Cha IJ, Shin JG: Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. Xenobiotica. 2005 Jan;35(1):27-38. doi: 10.1080/00498250400026472 . [PubMed:15788366]
  5. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [PubMed:15258107]
  6. Kita T, Sakaeda T, Baba T, Aoyama N, Kakumoto M, Kurimoto Y, Kawahara Y, Okamura N, Kirita S, Kasuga M, Okumura K: Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull. 2003 Mar;26(3):386-90. [PubMed:12612455]
  7. Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T: Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol. 2004 Nov;44(11):1223-9. doi: 10.1177/0091270004269015. [PubMed:15496639]
  8. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA: Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997 Jul;25(7):853-62. [PubMed:9224780]
  9. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17. [PubMed:19076159]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7. [PubMed:11770010]
  2. Kodaira C, Sugimoto M, Nishino M, Yamade M, Shirai N, Uchida S, Ikuma M, Yamada S, Watanabe H, Hishida A, Furuta T: Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. Eur J Clin Pharmacol. 2009 Jun;65(6):593-600. doi: 10.1007/s00228-009-0625-8. Epub 2009 Feb 24. [PubMed:19238367]

Drug created on June 13, 2005 07:24 / Updated on September 24, 2018 02:41